What is it about?
In this paper we show that two novel inflammatory biomarkers, blood count of CD45-positive platelets and neutrophil to lymphocyte ratio, are elevated in patients with coronary artery disease and type 2 diabetes mellitus, who developed in-stent restenosis during the first year after drug-eluting stent implantation.
Featured Image
Why is it important?
This is significant because in-stent restenosis after drug-eluting stent implantation remains an important adverse outcome of coronary angioplasty. The possibility to predict and prevent restenosis can improve results of coronary artery stenting.
Perspectives
We built a logit regression model, which showed that the combination of 3 factors (namely: CD45-positive platelets, neutrophil to lymphocyte ratio and diabetes mellitus) possess the higher ability to predict restenosis occurrence, than those factors, taken separately.
Zufar Gabbasov
Institute of Experimental Cardiology Cardiology Research Center
Read the Original
This page is a summary of: Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease, Clinical and Applied Thrombosis/Hemostasis, May 2018, SAGE Publications,
DOI: 10.1177/1076029618771752.
You can read the full text:
Resources
Contributors
The following have contributed to this page
